Artisan Non-U.S. Small-Mid Growth Strategy

QUARTERLY
Commentary

As of 30 September 2021

Investment Process

We seek long-term investments in high-quality businesses exposed to structural growth themes that can be acquired at sensible valuations in a contrarian fashion and are led by excellent management teams.

Investing with Tailwinds

We identify structural themes at the intersection of growth and change with the objective of investing in companies having meaningful exposure to these trends. Themes can be identified from both bottom-up and top-down perspectives.

High-Quality Businesses

We seek future leaders with attractive growth characteristics that we can own for the long term. Our fundamental analysis focuses on those companies exhibiting unique and defensible business models, high barriers to entry, proven management teams, favorable positions within their industry value chains and high or improving returns on capital. In short, we look to invest in small companies that have potential to become large.

A Contrarian Approach to Valuation

We seek to invest in high-quality businesses in a contrarian fashion. Mismatches between stock price and long-term business value are created by market dislocations, temporary slowdowns in individual businesses or misperceptions in the investment community. We also examine business transformation brought about by management change or restructuring.

Manage Unique Risks of International Small- and Mid-Cap Equities

International small- and mid-cap equities are exposed to unique investment risks that require managing. We define risk as permanent loss of capital, not share price volatility. We manage this risk by having a long-term ownership focus, understanding the direct and indirect security risks for each business, constructing the portfolio on a well-diversified basis and sizing positions according to individual risk characteristics.

Team Overview

Our team is intellectually curious about the world and how it is changing. Each team member is passionate about small company investing and discovering businesses with meaningful and open-ended growth opportunities.

Portfolio Management

Rezo Kanovich
Portfolio Manager

Investment Results (% USD)

As of 30 September 2021	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Inception[1]
			Average Annual Total Returns				
Composite — Gross	**-0.75**	**5.70**	**25.15**	—	—	—	**28.18**
Composite — Net	**-1.00**	**4.92**	**23.93**	—	—	—	**26.89**
MSCI All Country World ex USA SMID Index	-0.94	9.48	28.94	—	—	—	15.90
MSCI All Country World ex USA Small Cap Index	0.00	12.23	33.06	—	—	—	17.81

Annual Returns (% USD) 12 months ended 30 September

	2017	2018	2019	2020	2021
Composite — Gross	—	—	—	**29.81**	**25.15**

Source: Artisan Partners/MSCI. Returns for periods less than one year are not annualized. [1]Composite inception: 1 January 2019.

Past performance does not guarantee and is not a reliable indicator of future results. Current performance may be lower or higher than the performance shown. Composite performance has been presented in both gross and net of investment management fees.

Investment Risks: Investments will rise and fall with market fluctuations and investor capital is at risk. Investors investing in strategies denominated in non-local currency should be aware of the risk of currency exchange fluctuations that may cause a loss of principal. These risks, among others, are further described near the back of this document, which should be read in conjunction with this material.

Investing Environment

Global equities pulled back in Q3, in part, on expectations for less accommodative monetary policy across several key markets. Ongoing supply chain issues and investor reaction to certain rate-sensitive sectors also contributed to volatility. While developed markets ended largely flat for the quarter, emerging markets fell sharply. Investors demanded higher yields, with the 10-year Treasury starting 2021 at 0.92% and finishing Q3 above 1.5%. Within the MSCI ACWI ex USA SMID Index, the consumer discretionary and health care sectors were the largest laggards, while the energy and financials sectors produced the strongest returns.

The third quarter did not offer investors an overarching narrative. Instead, there was a lot of distracting short-term noise and cyclical gyrations. We kept our heads down and continued to do what we have always done—that is, focus on opportunities that emerge at the intersection of growth and change and look for companies with characteristics that will protect long-term earnings power and help to weather market volatility. Our experience has consistently demonstrated to us that what matters most for smaller companies is innovation, talented management teams, durable competitive advantages and strong balance sheets.

One important characteristic, especially in today's market environment, that can provide a company pricing power is high value-added bottleneck positioning. We consider a company to have high value-added bottleneck positioning when its products or services occupy a particularly important position in an industry's value chain but represent only a small portion of the end product's total production cost. Having an outsized value relative to cost is particularly important for many smaller companies that can rarely compete on scale with larger competitors. A company that plays a mission critical role is likely to have strong market position, brand recognition, product differentiation and high customer intimacy due to factors such as reliability, safety and ease of use. The resilience afforded to businesses in this circumstance is also attractive to us as long-term investors seeking sustainable success. Assuming they continue to innovate, we find such companies carry a lower risk of being disintermediated.

Certain long-term implications of the COVID-19 pandemic have become clear in various industries—namely, businesses are seeking to bring production closer to their customers, shorten supply chains and lead times and minimize disruptions. In addition, the trend toward specialization continues to accelerate, allowing for best-in-class players to emerge. These shifts only increase the significance of high value-added bottlenecks, which is one of the more diverse themes in our portfolio by industry, sector and geographic makeup.

Our forthcoming portfolio manager Viewpoints, "Punching Above Their Weight Class: High Value-Added Bottlenecks," discusses this theme in greater depth. However, we wanted to provide a couple of examples here to bring this concept to life. One such example is UK-based Rotork, a machinery business positioned as a leader in electric actuators providing fluid controls for water, chemical, oil and gas plants. Electric actuators are structurally gaining market share from pneumatic and hydraulic actuators, which have less precise control, require more maintenance and emit hazardous pollutants. An actuator could be priced at just 20% of the price of the valve on which it is placed, and valves make up a modest percentage of a process plant's total cost. However, the actuator is critical to controlling process parameters and—when necessary—responding to emergencies. While the actuator business may seem like fertile ground for competition, there are significant barriers to entry due to the high degree of specialization required. Rotork's superior products allow it to price at a premium to competitors and even win projects over more integrated competitors that can also supply the project's valves.

Another example is Swiss-based Siegfried, which operates in the rapidly innovative life sciences industry. Siegfried is a contract development and manufacturing organization that offers products and tailor-made service packages to be seamlessly embedded in the value chain of its pharmaceutical partners. A wide-ranging portfolio includes the development of intermediates and active substances, development services for ready-made drugs, drug approval, production, packaging and logistics. As a former fully integrated pharmaceutical company, Siegfried's customers benefit from synergies, technological competence with strict quality controls and a global presence. In turn, Siegfried has earned brand recognition, preferential partner status and pricing power.

As a reminder, we seek enduring portfolio themes representing a decade-long tailwind to the changing dynamics of a given industry. This philosophy is by nature antithetical to the fits and starts of cyclical trade activity, much of which has dominated the recent environment. That being said, as bottom-up investors who look to be contrarian, the underlying opportunity set steadily evolves due to valuations, business fundamentals and changing competitive landscapes. The result of our approach is a carefully constructed portfolio of idiosyncratic investments across sectors, industries and geographies. This diversity is aimed to provide the portfolio with resilience in different market environments. We are aware of macroeconomic dynamics, but they do not drive our investment process. We try to find companies with management teams that can navigate a challenging operating environment and capitalize on the structural changes transforming the post-pandemic world. We maintain a long-term view and will opportunistically take advantage of short-term volatility to invest in high-quality companies at attractive valuations.

Performance Discussion

Our portfolio modestly trailed the index in Q3 as holdings in the consumer discretionary and health care sectors dampened absolute and relative returns. On the positive side, our information technology and industrials holdings provided a relative lift.

Our largest decliners in Q3 were MorphoSys, ASOS, boohoo Group, Glaukos and Metso Outotec. Shares of MorphoSys, a name we've discussed in-depth in recent letters, have declined due to soft sales for Monjuvi® and news of the company's recent acquisition of Constellation Pharmaceuticals, which it funded through monetizing part of its royalty portfolio. In our opinion, these recent developments have elevated MorphoSys' risk profile. As a result, we trimmed our position during the quarter and are reassessing the company's future prospects.

While ASOS and boohoo Group, UK-based online fashion retailers, have benefited from increased online spending during the pandemic, their shares have recently retreated mainly due to supply chain issues and higher freight costs. These challenges are not unique to ASOS and boohoo; they are industrywide across large and small competitors. Investor concerns of growing competition from China and tough year-over-year comparisons also weighed on their respective stock prices. In the medium term, ASOS and boohoo are building local fulfillment centers, which will structurally lower distribution costs over time. Moreover, as the volume of international travel returns to pre-pandemic levels, passenger planes can also distribute a large number of shipments at lower costs, making today's higher freight costs transient. Our focus remains on the long-term success of these companies, which, in our view, rests on their differentiated fashion proposition and the efficiency of their platforms. Over recent years, ASOS and boohoo strengthened their customer bases and used their balance sheet strength to acquire high street brands with the potential for meaningfully increased scale. ASOS acquired globally relevant Topshop and Topman, and its platform now includes over 850 brands, including ASOS Design. Boohoo made several acquisitions, including Karen Millen, Coast, Dorothy Perkins and Burton Menswear.

Glaukos, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, has evolved from a single-product company to a comprehensive ophthalmology company. Glaukos has been very successful commercializing its iStent inject® device that is used to treat glaucoma patients in combination with cataract surgery. The long-term opportunities for Glaukos stem from a number of nascent commercial launches and a pipeline of R&D projects, including Avedro, a leading treatment for keratoconus (cone-shaped cornea that causes distorted vision) and iDose®, an implant for extended-release of glaucoma medication over 6-12 months that has the potential to revolutionize the market. The stock was one of the best performers last year and pulled back recently in response to the news that Medicare may cut reimbursement rates on iStent. The reimbursement cuts are still in the proposal stage, and we believe the company has a strong portfolio of products to ultimately navigate this challenge. More importantly, the long-term value of Glaukos' commercial platform in the pipeline is what underpins our investment thesis. We opportunistically added to our position during the quarter.

Metso Outotec, despite shares dropping modestly after tripling from their pandemic lows, remains one of our top-weighted positions. The management team has executed on multiple aspects of the ongoing transformation of its business. As a reminder, our investment thesis is threefold: 1) Metso is evolving from its prior life as a metal basher to a high value-added IoT (Internet of things)- and electrification-driven company focused on the automation of mining operations; 2) This transformation represents a long runway for margin improvement; and 3) We think the demand environment will be robust as electrification continues to drive the needs for copper, uranium and other metals. The short-term stock price decline resulted from concerns over volatility in the price for iron ore and demand for aggregates like concrete due to troubles in the Chinese real estate industry. These concerns are not material to our long-term thesis, and we applied our contrarianism by adding to our position.

Top contributors during the quarter were NICE, Intersect ENT, Kornit Digital, Alcon and Comet Holding. NICE, which we have spoken about many times, rewarded our patience following investor rotation away from 2020 "pandemic play" winners. The fundamentals of the business continue to be strong, and the penetration opportunity for call center software remains. NICE also boasts meaningful margin potential, with growth stemming from the cross-sell/upsell opportunity into increased artificial intelligence and analytics across its suite of products—including its platform for financial fraud and compliance.

During the quarter, Medtronic announced its acquisition of Intersect ENT. Intersect ENT focuses on treatments for chronic sinusitis, which is a large, underserved and fragmented market with significant growth potential. The acquisition will expand Medtronic's access to the ear, nose and throat market most notably through Intersect's balloon sinus dilation tools and surgical navigation systems. Intersect's offerings will complement Medtronic's product suite.

Kornit continues to excel in its role as an enabler of the apparel industry's structural shift to automation and instant fashion. Unsold inventory (30% of all garments produced) wastes 21 million tons of textile and 28 trillion liters of water per year (72 years of the US's total water consumption), and Kornit's technology meaningfully decreases the environmental impact. This quarter, we had an opportunity to witness customer enthusiasm of this technology at a New York fashion show. It is obvious to us that Kornit is on the right side of history. Kornit's premier customer relationships and the long tail of high-margin proprietary ink consumables and services, support sustainable cash flows.

Alcon, a manufacturer of surgical equipment and vision care products, was punished at the beginning of the pandemic due to meaningfully fewer elective procedures performed. We took advantage of this opportunity to purchase a premier company at an extremely attractive valuation. Alcon's shares have since rebounded as the shutdown continues to abate in developed markets. We like the company's high level of profitability, as customers tend not to be price sensitive when it comes to their vision care, and we believe Alcon has meaningful opportunities to grow its top line and improve margins.

Moreover, aging demographics in the developed and emerging world, increased spending on health care and advances in material science borne out of the miniaturization and robotization of procedures support long-term earnings.

Swiss-based engineer Comet Holding manufactures components for high-power devices used in processing the next-generation of semiconductors. There is an increasing need for higher power in these processes, and Comet is a market leader in radio frequency (RF) match boxes, also known as vacuum capacitors, and impedance matching networks, with approximately 70% of market share. This is a highly concentrated market that will grow as these devices are required to support trends toward further miniaturization in the semiconductor industry. Match is universally needed, which, in our view, places us on the right side of history. Notably, Comet's RF generator opens up a new market for the company that is twice the size of that of RF match box. It is a high margin and high return on capital business because the focus on engineering is weighted more toward intellectual property than hardware intensity. Comet has a relatively new CEO who has driven growth in the business and divested from non-core products. We are also interested in Comet's product pipeline, including x-ray manufacturing technologies.

Positioning

Our contrarian approach to valuation has been of particular importance over the last 18 months. Markets have oscillated between periods of fear and uncertainty and periods of irrational momentum buying and wholesale selling of certain sectors. As always, we continued to adhere to our time-tested investment approach, focusing on individual company fundamentals and patiently waiting for entry points that may allow us to double our shareholders' money over five years. Perceived adversity and market volatility over shorter time frames may cause anxiety for some investors, but we welcome such an environment that makes it possible to purchase high-quality companies in an opportunistic fashion.

A risk-aware mindset governs everything we do, from our approach to business model analysis to the portfolio's diversified nature. We incrementally build positions over time as we learn more about the companies through conversations with management and adjust position sizes according to valuations and the execution of strategic initiatives. This disciplined practice helps support comfortable risk/reward margins.

A recent example is Toshiba, which is now at a more meaningful weight months after initiating a position in Q1 of this year. A business with such global name recognition will surprise many readers, who may associate Toshiba's brand with the glory days of its past and involvement in increasingly commoditized business lines. However, small- and mid-cap companies come in various shapes, and opportunities may come along when formerly large companies become small ones. Having transformed itself by stripping noncore businesses and partially monetizing its successful flash memory business Kioxia, we believe the future is bright. The remaining businesses, in our view, are extraordinarily undervalued and positioned on the right side of history. Toshiba's long-standing commitment to R&D has created significant intellectual property in areas of power generation, hydrogen technologies and quantum computing, and the businesses is buttressed by its very steady infrastructure services operation.

We believe the most attractive investments have enduring business models and differentiation that transcends short-term market cycles. Companies that fit this profile—companies on which we perform rigorous due diligence and look to own throughout various market cycles—are those we think offer the best opportunity for long-term growth.

For more information: Visit www.artisanpartners.com

Investment Risks: International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging markets. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Growth securities may underperform other asset types during a given period. These risks, among others, are further described in Artisan Partners Form ADV, which is available upon request.

Unless otherwise indicated, the Artisan Strategy characteristics relate to that of an investment composite or a representative account managed within a composite. It is intended to provide a general illustration of the investment strategy and considerations used by Artisan Partners in managing that strategy. Individual accounts may differ, at times significantly, from the reference data shown due to varying account restrictions, fees and expenses, and since-inception time periods, among others. Where applicable, this information is supplemental to, and not to be construed with, a current or prospective client's investment account information. References to individual security performance relate to a representative account in the composite. Individual holding periods may differ.

Securities referenced may not be representative of all portfolio holdings. Securities of the same issuer are aggregated to determine a holding's portfolio weight. Portfolio statistics calculations exclude outlier data and certain securities which lack applicable attributes, such as private securities. Artisan Partners may substitute information from a related security if unavailable for a particular security. This material is as of the date indicated and is subject to change without notice. Totals may not sum due to rounding.

Attribution is used to evaluate the investment management decisions which affected the portfolio's performance when compared to a benchmark index. Attribution is not exact, but should be considered an approximation of the relative contribution of each of the factors considered.

Net-of-fees composite returns were calculated using the highest model investment advisory fees applicable to portfolios within the composite. Fees may be higher for certain pooled vehicles and the composite may include accounts with performance-based fees. All performance results are net of commissions and transaction costs, and have been presented gross and net of investment advisory fees. Dividend income is recorded net of foreign withholding taxes on ex-dividend date or as soon after the ex-dividend date as the information becomes available to Artisan Partners. Interest income is recorded on the accrual basis. Performance results for the Index include reinvested dividends and are presented net of foreign withholding taxes but, unlike the portfolio's returns, do not reflect the payment of sales commissions or other expenses incurred in the purchase or sale of the securities included in the indices.

MSCI All Country World ex USA SMID Index measures the performance of small- and mid-cap companies in developed and emerging markets excluding the US. MSCI All Country World Small Cap Index measures the performance of small-cap companies in developed and emerging markets. The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used to create indices or financial products. This report is not approved or produced by MSCI.

The Global Industry Classification Standard (GICS®) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

This summary represents the views of the portfolio manager as of 30 Sep 2021. Those views and portfolio holdings are subject to change and Artisan Partners disclaims any obligation to advise investors of such changes. The discussion of portfolio holdings does not constitute a recommendation of any individual security. For a complete list of holdings by contribution to the strategy, refer to the Contributors to Return chart.

Return on Capital (ROC) is a measure of how effectively a company uses the money (borrowed or owned) invested in its operations.

This material is provided for informational purposes without regard to your particular investment needs. This material shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein. In no event shall Artisan Partners have any liability for direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) losses or any other damages resulting from the use of this material.

Artisan Partners Limited Partnership (APLP) is an investment adviser registered with the U.S. Securities and Exchange Commission (SEC). Artisan Partners UK LLP (APUK) is authorized and regulated by the Financial Conduct Authority and is a registered investment adviser with the SEC. APEL Financial Distribution Services Limited (AP Europe) is authorized and regulated by the Central Bank of Ireland. APLP, APUK and AP Europe are collectively, with their parent company and affiliates, referred to as Artisan Partners herein. Artisan Partners is not registered, authorised or eligible for an exemption from registration in all jurisdictions. Therefore, services described herein may not be available in certain jurisdictions. This material does not constitute an offer or solicitation where such actions are not authorised or lawful, and in some cases may only be provided at the initiative of the prospect. Further limitations on the availability of products or services described herein may be imposed.

This material is only intended for investors which meet qualifications as institutional investors as defined in the applicable jurisdiction where this material is received, which includes only *Professional Clients or Eligible Counterparties* as defined by the Markets in Financial Instruments Directive (MiFID) where this material is issued by APUK or AP Europe. This material is not for use by retail investors and may not be reproduced or distributed without Artisan Partners' permission.

In the United Kingdom, issued by APUK, 25 St. James's St., Floor 3, London SW1A 1HA, registered in England and Wales (LLP No. OC351201). Registered office: Reading Bridge House, Floor 4, George St., Reading, Berkshire RG1 8LS. In Ireland, issued by AP Europe, Fitzwilliam Hall, Fitzwilliam Pl, Ste. 202, Dublin 2, D02 T292. Registered office: 70 Sir John Rogerson's Quay, Dublin 2, D02 R296 (Company No. 637966).

Australia: This material is directed at wholesale clients only and is not intended for, or to be relied upon by, private individuals or retail investors. Artisan Partners Australia Pty Ltd is a representative of APLP (ARBN 153 777 292) and APUK (ARBN 603 522 649). APLP and APUK are respectively regulated under US and UK laws which differ from Australian laws and are exempt from the requirement to hold an Australian financial services license under the Australian Corporations Act 2001 in respect to financial services provided in Australia.

Canada: This material is distributed in Canada by APLP and/or Artisan Partners Distributors LLC, which conduct activities in Canada under exemptions from the dealer, portfolio manager and investment fund manager registration requirements of applicable Canadian securities laws. This material does not constitute an offer of services in circumstances where such exemptions are not available. APLP advisory services are available only to investors that qualify as "permitted clients" under applicable Canadian securities laws.

For Institutional Investors – Not for Onward Distribution

Artisan Non-U.S. Small-Mid Growth Strategy

Quarterly Contribution to Return (% USD)

As of 30 September 2021

Top Contributors	Average Weight	Contribution to Return	Ending Weight
Nice Ltd	3.56	0.51	3.65
Intersect ENT Inc	0.86	0.51	0.42
Kornit Digital Ltd	2.70	0.39	2.96
Alcon Inc	1.75	0.27	1.86
Comet Holding AG	1.01	0.26	0.90
Fortnox AB	1.10	0.22	1.20
IMCD NV	1.19	0.22	1.24
Jeol Ltd	0.96	0.20	0.96
CyberArk Software Ltd	1.11	0.20	1.21
SG Holdings Co Ltd	2.25	0.19	2.14
Alkermes PLC	0.82	0.18	0.88
Hennge KK	0.35	0.17	0.54
IndiaMart InterMesh Ltd	0.84	0.14	0.92
Morinaga Milk Industry Co Ltd	0.75	0.13	0.80
Radware Ltd	1.42	0.13	1.45
The Descartes Systems Group Inc	0.78	0.12	0.84
Belimo Holding AG	0.86	0.12	0.89
Tecan Group AG	0.69	0.11	0.66
Acceleron Pharma Inc	0.31	0.10	0.41
Legend Biotech Corp	0.48	0.10	0.58
ViewRay Inc	1.18	0.10	1.37
Genmab A/S	1.17	0.09	1.14
Trainline PLC	0.61	0.09	0.61
JD Sports Fashion PLC	0.76	0.09	0.70
Kinaxis Inc	0.85	0.08	0.85
Howden Joinery Group PLC	1.26	0.08	1.20
Oxford Biomedica PLC	0.55	0.08	0.60
Koninklijke DSM NV	1.02	0.08	1.00
Money Forward Inc	0.67	0.08	0.71
Fujitec Co Ltd	1.24	0.07	1.21
Inspire Medical Systems Inc	0.38	0.07	0.42
Azbil Corp	1.66	0.07	1.70
Fabrinet	1.06	0.07	1.11
JET2 PLC	1.47	0.06	1.71
Altus Group Ltd	1.04	0.06	1.07
GMO Financial Gate Inc	0.02	0.06	0.40
Alnylam Pharmaceuticals Inc	0.47	0.05	0.48
Lectra	1.08	0.04	1.06
Davide Campari-Milano NV	0.76	0.04	0.77
DSV A/S	1.02	0.03	0.98
Ingersoll Rand Inc	1.00	0.03	0.99
WNS Holdings Ltd	1.18	0.03	1.18
Ergomed PLC	0.34	0.03	0.35
Kobe Bussan Co Ltd	0.51	0.03	0.46
CKD Corp	1.38	0.03	1.50
Myriad Genetics Inc	0.48	0.03	0.56
Rami Levy Chain Stores Hashikma Marketing 2006 Ltd	0.24	0.03	0.26
Electrocomponents PLC	1.51	0.02	1.50
MaxCyte Inc	0.56	0.02	0.40
YouGov PLC	0.56	0.02	0.53
Rohm Co Ltd	0.71	0.02	0.71
Vestas Wind Systems A/S	0.68	0.02	0.74
B&M European Value Retail SA	0.69	0.02	0.69

Continued on next page.

Bottom Contributors	Average Weight	Contribution to Return	Ending Weight
MorphoSys AG	0.96	-0.50	0.50
ASOS PLC	0.90	-0.46	0.68
boohoo Group PLC	1.30	-0.46	0.99
Glaukos Corp	0.85	-0.43	0.81
Metso Outotec Oyj	1.79	-0.41	1.79
Carenet Inc	0.84	-0.32	0.73
Cree Inc	1.29	-0.23	1.28
Ambu A/S	0.86	-0.23	0.74
ConvaTec Group PLC	1.75	-0.21	1.59
Raccoon Holdings Inc	0.64	-0.21	0.49
Daikokutenbussan Co Ltd	0.89	-0.19	0.89
Alphawave IP Group PLC	0.53	-0.18	0.34
Petrobras Distribuidora SA	0.81	-0.16	0.67
Oncopeptides AB	0.07	-0.15	0.00
Orchard Therapeutics PLC	0.18	-0.12	0.08
Afya Ltd	0.46	-0.12	0.40
Real Matters Inc	0.19	-0.12	0.15
AIXTRON SE	1.27	-0.11	1.13
Global Blood Therapeutics Inc	0.32	-0.11	0.00
Flexion Therapeutics Inc	0.13	-0.10	0.00
Elekta AB	0.42	-0.09	0.35
Ubicom Holdings Inc	0.38	-0.09	0.38
Notre Dame Intermedica Participacoes SA	0.38	-0.08	0.34
Almirall SA	0.86	-0.08	0.81
Rumo SA	0.38	-0.07	0.32
BasWare Oyj	0.35	-0.07	0.29
Fevertree Drinks PLC	0.50	-0.07	0.47
Reata Pharmaceuticals Inc	0.20	-0.07	0.17
Roland Corp	0.64	-0.07	0.61
Carlsberg AS	0.52	-0.07	0.48
KION Group AG	0.55	-0.07	0.49
Balfour Beatty PLC	0.44	-0.06	0.40
Agilysys Inc	0.79	-0.06	0.78
Hamburger Hafen und Logistik AG	0.49	-0.06	0.48
Establishment Labs Holdings Inc	0.26	-0.06	0.24
Essa Pharma Inc	0.04	-0.06	0.00
ALK-Abello A/S	0.56	-0.06	0.48
Gaztransport Et Technigaz SA	0.85	-0.06	0.93
I-Mab	0.32	-0.06	0.31
Tel Aviv Stock Exchange Ltd	0.34	-0.05	0.33
CAE Inc	1.48	-0.05	1.50
Lantheus Holdings Inc	0.59	-0.05	0.58
Zogenix Inc	0.31	-0.04	0.39
Madrigal Pharmaceuticals Inc	0.21	-0.04	0.18
Revenio Group Oyj	0.28	-0.04	0.24
Britvic PLC	0.68	-0.04	0.61
Quotient Ltd	0.11	-0.04	0.05
BioCryst Pharmaceuticals Inc	0.49	-0.04	0.43
HomeServe PLC	0.59	-0.03	0.54
Symrise AG	0.76	-0.03	0.70
Model N Inc	1.17	-0.03	1.16
Toshiba Corp	1.31	-0.03	1.47
New Work SE	0.15	-0.03	0.08

Artisan Non-U.S. Small-Mid Growth Strategy

Quarterly Contribution to Return (% USD)

As of 30 September 2021

Top Contributors (continued)	Average Weight	Contribution to Return	Ending Weight
Vaisala Oyj	0.33	0.02	0.32
Obic Co Ltd	0.50	0.01	0.51
Burckhardt Compression Holding AG	0.38	0.01	0.40
TechMatrix Corp	0.41	0.01	0.35
Plus Alpha Consulting Co Ltd	0.03	0.01	0.12
St James's Place PLC	1.10	0.01	1.03
TECSYS Inc	0.11	0.01	0.28
Varex Imaging Corp	0.24	0.00	0.47
en Japan Inc	0.38	0.00	0.40
Argenx SE	0.43	0.00	0.42
Carl Zeiss Meditec AG	0.32	0.00	0.29
Kitanotatsujin Corp	0.18	0.00	0.05
Sagami Rubber Industries Co Ltd	0.00	0.00	0.00
Rotork PLC	1.54	-0.00	1.51
Cash Holdings	2.54	-0.00	4.62

Bottom Contributors (continued)	Average Weight	Contribution to Return	Ending Weight
SSP Group PLC	0.06	-0.03	0.00
Ossur HF	0.57	-0.02	0.53
AAK AB	0.92	-0.02	0.85
AVEVA Group PLC	0.67	-0.02	0.59
Verastem Inc	0.06	-0.02	0.06
Compugen Ltd	0.05	-0.02	0.05
SimCorp A/S	0.37	-0.02	0.33
Siegfried Holding AG	0.82	-0.02	0.72
Max Stock Ltd	0.28	-0.01	0.28
Temairazu Inc	0.30	-0.01	0.33
Baloise Holding AG	0.86	-0.01	0.82
Barry Callebaut AG	0.79	-0.01	0.72
eSOL Co Ltd	0.05	-0.01	0.00
Telix Pharmaceuticals Ltd	0.12	-0.00	0.12
Nevro Corp	0.23	-0.00	0.46

Source: Artisan Partners/FactSet. **Performance is historical and is not a reliable indicator of future results.** As of 30 Sep 2021. These investments made the greatest contribution to, or detracted most from, performance during the period based on a representative account within the strategy Composite. Upon request, Artisan will provide: (i) the calculation methodology and/or (ii) a list showing the contribution of each holding to overall performance during the measurement period. Securities of the same issuer are aggregated to determine the weight in the portfolio. % Contribution to Return is calculated by FactSet by multiplying a security's weight in the portfolio by its in portfolio return for the period referenced and does not take into account expenses of the portfolio. Purchases/sales are accounted for by using end of the day prices, which may or may not reflect the actual purchase/sale price realized by the portfolio.